Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease
10.11665/j.issn.1000-5048.20220405
- VernacularTitle:非酒精性脂肪性肝病的联合疗法和递送策略
- Author:
Yanmei WANG
1
;
Lei YANG
;
Xiaofei XIN
;
Lifang YIN
Author Information
1. 中国药科大学药学院药剂系
- Publication Type:Journal Article
- Keywords:
non-alcoholic fatty liver disease;
liver fibrosis;
combination therapy;
chemogene therapy;
targeting strategy
- From:
Journal of China Pharmaceutical University
2022;53(4):423-432
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease (NAFLD) is a series of chronic liver diseases strongly associated with the metabolic disorder with an increasing rate of worldwide prevalence.Due to its complicated pathogenesis, only Saroglitazar has been approved by Indian Drug Controller General (DCGI) as a PPAR-α/γ dual agonist to treat non-cirrhotic non-alcoholic steatohepatitis.Combination therapy, which can target same or different signaling pathways of NAFLD pathogenesis, has been developed to achieve synergistic therapeutic efficacy.Currently, small-molecule drug combination, RNAi combination therapy, and chemogene therapy are proposed as promising strategies in NAFLD treatment.In addition, designing a smart, safe and effective drug delivery system is key to realizing the druggability, clinical translation and industrialization of small molecule drugs and gene drugs.This review summarizes the research status and delivery system of small-molecule drug combination, RNAi combination therapy, and chemogene therapy, in the hope of providing some novel insight for the treatment of NAFLD.
